Organon Company Leadership
| OGN Stock | USD 15.28 0.39 2.62% |
Organon employs about 10 K people. The company is managed by 16 executives with a total tenure of roughly 23334 years, averaging almost 1458.0 years of service per executive, having 625.0 employees per reported executive. Analysis of Organon's management performance can provide insight into the firm performance.
Organon |
Organon's latest congressional trading
Congressional trading in companies like Organon, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Organon by those in governmental positions are based on the same information available to the general public.
| 2021-06-15 | Representative Scott Franklin | Acquired Under $15K | Verify |
Organon Management Team Effectiveness
The company has Return on Asset of 0.0791 % which means that on every $100 spent on assets, it made $0.0791 of profit. This is way below average. Organon's management efficiency ratios could be used to measure how well Organon manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Capital Employed is likely to grow to 0.29, while Return On Tangible Assets are likely to drop 0.14. At this time, Organon's Other Current Assets are very stable compared to the past year. As of the 25th of November 2024, Non Current Assets Total is likely to grow to about 7.7 B, while Total Assets are likely to drop about 11.9 B.Organon Quarterly Income Before Tax |
|
Organon Workforce Comparison
Organon Co is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 731,315. Organon claims roughly 10,000 in number of employees contributing just under 2% to equities under Health Care industry.
Organon Profit Margins
The company has Net Profit Margin of 0.2 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.48 | 0.5984 |
|
| |||||
| Net Profit Margin | 0.25 | 0.1633 |
|
| |||||
| Operating Profit Margin | 0.34 | 0.2122 |
|
| |||||
| Pretax Profit Margin | 0.1 | 0.1075 |
|
| |||||
| Return On Assets | 0.0806 | 0.0848 |
|
|
Organon Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Organon insiders, such as employees or executives, is commonly permitted as long as it does not rely on Organon's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Organon insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.3333 | 1 | 3 | 6,446 | 28,085 |
| 2024-09-01 | 0.75 | 9 | 12 | 61,839 | 68,140 |
| 2024-06-01 | 1.1111 | 20 | 18 | 155,481 | 72,453 |
| 2024-03-01 | 0.8305 | 49 | 59 | 2,262,267 | 504,288 |
| 2023-09-01 | 0.5 | 2 | 4 | 35,242 | 50,666 |
| 2023-06-01 | 0.8158 | 31 | 38 | 189,771 | 99,215 |
| 2023-03-01 | 0.9048 | 38 | 42 | 1,539,883 | 199,227 |
| 2022-09-01 | 0.5 | 2 | 4 | 35,233 | 50,439 |
| 2022-06-01 | 0.6176 | 21 | 34 | 113,157 | 72,411 |
| 2022-03-01 | 1.375 | 22 | 16 | 634,309 | 73,499 |
| 2021-09-01 | 6.0 | 18 | 3 | 465,815 | 13,958 |
| 2021-06-01 | 56.0 | 112 | 2 | 3,568,101 | 253,516,000 |
Organon Notable Stakeholders
An Organon stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Organon often face trade-offs trying to please all of them. Organon's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Organon's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Matthew Walsh | Executive CFO | Profile | |
| Matthew CFA | Executive CFO | Profile | |
| Meghan Rivera | US Director | Profile | |
| Kirke Weaver | General VP | Profile | |
| Susan ONeal | Chief Officer | Profile | |
| Rebecca Edwards | Chief Officer | Profile | |
| Rachel Stahler | Executive Officer | Profile | |
| Susanne Fiedler | Executive Officer | Profile | |
| Daniel Karp | Executive Development | Profile | |
| Aaron Falcione | Executive Officer | Profile | |
| Geralyn Ritter | Sustainability Affairs | Profile | |
| Kevin Ali | CEO Director | Profile | |
| Jennifer Halchak | Vice Relations | Profile | |
| Joseph Morrissey | Executive Supply | Profile | |
| Vittorio Nisita | Executive Services | Profile | |
| MD JD | Ex RD | Profile |
About Organon Management Performance
The success or failure of an entity such as Organon often depends on how effective the management is. Organon management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Organon management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Organon management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.15 | 0.14 | |
| Return On Capital Employed | 0.15 | 0.29 | |
| Return On Assets | 0.08 | 0.08 | |
| Return On Equity | (14.61) | (13.88) |
Organon Workforce Analysis
Traditionally, organizations such as Organon use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Organon within its industry.Organon Manpower Efficiency
Return on Organon Manpower
| Revenue Per Employee | 626.3K | |
| Revenue Per Executive | 391.4M | |
| Net Income Per Employee | 102.3K | |
| Net Income Per Executive | 63.9M | |
| Working Capital Per Employee | 159K | |
| Working Capital Per Executive | 99.4M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organon Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organon. If investors know Organon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organon listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.081 | Dividend Share 1.12 | Earnings Share 5.05 | Revenue Per Share 24.984 | Quarterly Revenue Growth 0.041 |
The market value of Organon is measured differently than its book value, which is the value of Organon that is recorded on the company's balance sheet. Investors also form their own opinion of Organon's value that differs from its market value or its book value, called intrinsic value, which is Organon's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organon's market value can be influenced by many factors that don't directly affect Organon's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Organon's value and its price as these two are different measures arrived at by different means. Investors typically determine if Organon is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organon's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.